38,534 Shares in uniQure (NASDAQ:QURE) Purchased by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC acquired a new stake in shares of uniQure (NASDAQ:QURE - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 38,534 shares of the biotechnology company's stock, valued at approximately $681,000. Susquehanna Fundamental Investments LLC owned 0.08% of uniQure as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of QURE. Geode Capital Management LLC increased its position in shares of uniQure by 1.3% during the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company's stock worth $2,509,000 after purchasing an additional 6,362 shares in the last quarter. Franklin Resources Inc. acquired a new stake in uniQure during the third quarter valued at approximately $7,360,000. FNY Investment Advisers LLC acquired a new position in uniQure in the fourth quarter worth approximately $88,000. Sanders Morris Harris LLC raised its stake in shares of uniQure by 50.0% in the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company's stock valued at $1,803,000 after purchasing an additional 34,034 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in uniQure by 9.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock valued at $195,000 after purchasing an additional 969 shares during the period. Institutional investors and hedge funds own 78.83% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. StockNews.com upgraded shares of uniQure to a "sell" rating in a research report on Tuesday, March 11th. Chardan Capital restated a "buy" rating and set a $38.00 price objective on shares of uniQure in a research report on Tuesday. Wells Fargo & Company reduced their target price on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a research report on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and set a $70.00 price target on shares of uniQure in a report on Monday, April 21st. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $24.00 target price on shares of uniQure in a research note on Tuesday, January 21st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $38.80.

uniQure Stock Performance

Shares of NASDAQ:QURE traded up $1.53 on Thursday, hitting $11.59. 1,885,792 shares of the company were exchanged, compared to its average volume of 1,834,210. The firm has a market capitalization of $634.85 million, a P/E ratio of -2.34 and a beta of 0.10. The stock's 50 day moving average price is $12.16 and its 200 day moving average price is $11.97. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18.

Insider Transactions at uniQure

In related news, CFO Christian Klemt sold 2,916 shares of the firm's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $33,009.12. Following the transaction, the chief financial officer now owns 155,168 shares in the company, valued at approximately $1,756,501.76. This trade represents a 1.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 26,727 shares of the stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total transaction of $285,978.90. Following the transaction, the chief executive officer now directly owns 571,188 shares in the company, valued at $6,111,711.60. This trade represents a 4.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 90,830 shares of company stock worth $961,401 over the last ninety days. 4.74% of the stock is currently owned by company insiders.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.